SCHEMBL12830129

SCHEMBL12830129

Cc1ccc(-c2scc(NC(=O)c3cc4c(F)cccc4o3)c2C(=O)O)c(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.40
▸ POLB P06746 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ ALB P02768 1/20 0.38
▸ IL2 P60568 1/20 0.38
▸ RAB9A P51151 6/20 0.38
▸ TP53 P04637 3/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ CSNK2A2 P19784 1/20 0.36
▸ CSNK2B P67870 1/20 0.36
▸ CSNK2A1 P68400 1/20 0.36
▸ CSNK2A3 Q8NEV1 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ CACNA1B Q00975 1/20 0.35
▸ APBA1 Q02410 1/20 0.35
▸ MEN1 O00255 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12830118 0.87 RAB9A (0.53) NPC1POLBMAPTALDH1A1RAB9A
SCHEMBL1954504 0.84 MEN1 (0.46) NPC1MAPTALDH1A1ALBIL2
SCHEMBL12830971 0.83 AKR1C3 (0.42) NPC1POLBRAB9ATP53KDM4E
SCHEMBL12756305 0.81 DAGLA (0.36) NPC1MAPTALDH1A1IL2RAB9A
SCHEMBL12830020 0.78 RAB9A (0.50) NPC1POLBMAPTALDH1A1RAB9A
SCHEMBL12756472 0.78 AKR1C3 (0.43) NPC1ALBIL2RAB9ATP53
SCHEMBL12756369 0.78 KDM4E (0.34) NPC1POLBMAPTALDH1A1RAB9A
SCHEMBL12830443 0.77 RAB9A (0.55) NPC1POLBMAPTALDH1A1RAB9A
SCHEMBL1490260 0.77 RAB9A (0.41) NPC1POLBMAPTALDH1A1RAB9A
SCHEMBL12830948 0.76 MAPT (0.33) NPC1MAPTALDH1A1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 — — WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885POLB 4774/4885MAPT 1478/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885POLB 4774/4885MAPT 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback